Literature DB >> 2663767

Pulmonary disease following allogeneic bone marrow transplantation.

M Murray, D S O'Briain, J Prichard, S R McCann.   

Abstract

Bone marrow transplantation is the treatment of choice of many haematological disorders but its success is limited by two major complications, graft-versus-host disease (GVHD) and pulmonary disorders. Of the first 31 patients transplanted at St. James's Hospital (1984-1986) 16 (52%) had a successful outcome. Of the 15 patients who died, two died of GVHD and one of recurrent leukaemia. All others had severe pulmonary disease either causing death directly (9 cases) or contributing to death from toxic encephalopathy, carditis or recurrent leukaemia (1 case each). The principal forms of pulmonary disease were cytomegalovirus pneumonitis (4 cases), acute haemorrhagic pulmonary oedema (4 cases) and pneumocystis carinii pneumonia (2 cases). There were single cases of staphylococcal pneumonia and idiopathic pulmonary fibrosis. Aspergillus was a second pathogen in two cases. Pulmonary damage due to conditioning chemoradiotherapy and to GVHD probably underlies this high incidence of pulmonary disease. T-cell depletion to limit the incidence of GVHD together with increased prophylaxis against CMV and pneumocystis carinii will probably substantially reduce these complications in the near future.

Entities:  

Mesh:

Year:  1989        PMID: 2663767     DOI: 10.1007/bf02942059

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  19 in total

Review 1.  Lung damage from cytotoxic drugs.

Authors:  C H Collis
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

2.  Idiopathic interstitial pneumonia following bone marrow transplantation: the relationship with total body irradiation.

Authors:  T J Keane; J Van Dyk; W D Rider
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-10       Impact factor: 7.038

Review 3.  Pulmonary complications of bone marrow transplantation.

Authors:  M J Krowka; E C Rosenow; H C Hoagland
Journal:  Chest       Date:  1985-02       Impact factor: 9.410

Review 4.  Bone marrow transplantation in leukemia. Current status.

Authors:  G W Santos
Journal:  Cancer       Date:  1984-12-01       Impact factor: 6.860

5.  Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia.

Authors:  B Speck; M M Bortin; R Champlin; J M Goldman; R H Herzig; P B McGlave; H A Messner; R S Weiner; A A Rimm
Journal:  Lancet       Date:  1984-03-24       Impact factor: 79.321

6.  Main autopsy findings in bone marrow transplant patients.

Authors:  J A Bombí; A Cardesa; C Llebaría; A Rives; E Carreras; A Grañena; M T Jiménez de Anta
Journal:  Arch Pathol Lab Med       Date:  1987-02       Impact factor: 5.534

7.  Allogeneic bone marrow transplantation for 144 patients with severe aplastic anemia.

Authors:  M M Bortin; R P Gale; A A Rimm
Journal:  JAMA       Date:  1981-03-20       Impact factor: 56.272

8.  Bone marrow transplantation for acute myelogenous leukemia. Factors associated with early mortality.

Authors:  M M Bortin; R P Gale; H E Kay; A A Rimm
Journal:  JAMA       Date:  1983-03-04       Impact factor: 56.272

9.  Cytotoxic drug-induced lung disease.

Authors:  H D Sostman; R A Matthay; C E Putman
Journal:  Am J Med       Date:  1977-04       Impact factor: 4.965

10.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide.

Authors:  G W Santos; P J Tutschka; R Brookmeyer; R Saral; W E Beschorner; W B Bias; H G Braine; W H Burns; G J Elfenbein; H Kaizer
Journal:  N Engl J Med       Date:  1983-12-01       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.